• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国政府科技报告 >Intranasal Protollin(Trademark)/F1-V Vaccine Elicits Respiratory and Serum Antibody Responses and Protects Mice Against Lethal Aerosolized Plague Infection
【24h】

Intranasal Protollin(Trademark)/F1-V Vaccine Elicits Respiratory and Serum Antibody Responses and Protects Mice Against Lethal Aerosolized Plague Infection

机译：鼻内protollin（商标）/ F1-V疫苗引发呼吸和血清抗体反应并保护小鼠免受致命的雾化瘟疫感染

获取原文
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

F1-V is a recombinant plague antigen comprising the capsular (F1) and virulence-associated (V) proteins. Given intramuscularly with Alhydrogel, it protects mice against challenge, but is less effective in non-human primates against high-dose aerosolized Yersinia pestis challenge, perhaps because it fails to induce respiratory immunity. Intranasal immunization of mice with F1-V formulated with a Proteosome-based adjuvant (Protollin trademark), elicited high titers of specific IgA in lungs whereas intranasal F1-V alone or intramuscular Alhydrogel-adsorbed F1-V did not. The Protollin-adjuvanted F1-V vaccine also induced high serum titers of specific IgG, comparable to those induced by intramuscular Alhydrogel-adsorbed F1-V. Mice immunized intranasally with Protollin-F1-V were 100% protected against aerosol challenge with 170 LD50 of Y. pestis and 80% against 255 LD50.

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号